Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02477319 · ClinicalTrials.gov registry record

A Two-Part Multicenter Prospective Longitudinal Study of CFTR-dependent Disease Profiling in Cystic Fibrosis (PROSPECT)

A clinical trial of Cystic Fibrosis, sponsored by University of Alabama at Birmingham.

Completed
Registry status
452
Enrollment target
20
Study locations

NCT02477319: Completed study of Cystic Fibrosis, sponsored by University of Alabama at Birmingham.

NCT02477319 is a study of Cystic Fibrosis that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 452 participants, above the 177-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (155% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02477319, a study of Cystic Fibrosis, has completed, sponsored by University of Alabama at Birmingham.

COMPLETED
Registry status
452 participants
Enrollment target
20
Study locations

Study Summary

identify and validate biomarkers that might reflect partial restoration of CFTR function and can be used to monitor disease progression, and ii) evaluate the mechanistic effects of CFTR modulators and other relevant therapies in individuals with CF

Primary Outcome

This is the primary endpoint for Part A per the PROSPECT protocol. Mean sweat chloride was not reported for Part B, as it is not a relevant statistic. For cohort 1, sweat chloride is from day 0 only. For cohorts 2-3, sweat chloride was averaged from days 0, 14, 90 via a random intercept longitudinal model.

Conditions Studied

Interventions

  • OTHER Observational

Study Locations (20)

Missouri

  • Children's Mercy Hospital - Kansas City
  • Cardinal Glennon Children's Medical Center - St Louis
  • St. Louis Children's Hospital - St Louis

California

  • Childrens Hospital Los Angeles - Los Angeles
  • Lucile S. Packard Children's Hospital - Palo Alto

Colorado

  • The Children's Hospital Colarado - Aurora
  • National Jewish Health - Denver

Massachusetts

  • Massachusetts General Hospital - Boston
  • Children's Hospital Boston - Boston

Michigan

  • Children's Hospital of Michigan - Detroit
  • Devon Children's Hospital at Spectrum Health - Grand Rapids

New York

  • Women and Children's Hospital of Buffalo - Buffalo
  • Columbia University Medical Center - New York

Alabama

  • University of Alabama at Birmingham - Birmingham

Illinois

  • Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago

Trial Details

FieldValue
Enrollment Target 452 participants
Start Date 2015-03
Est. Completion 2018-07-27
University of Alabama at Birmingham

1,160 total trials

What the finished NCT02477319 record still lists

NCT02477319 is an observational study that tracks outcomes without assigning an intervention. The registered 452 participants enrollment target is mid-sized for trials with a published cap, above the 177-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (155% higher).

The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which Observational is the first listed.

NCT02477319 names 20 study sites across 13 states, led by Missouri, California, Colorado.

Frequently Asked Questions

What is clinical trial NCT02477319 about?

NCT02477319 is a clinical study titled "A Two-Part Multicenter Prospective Longitudinal Study of CFTR-dependent Disease Profiling in Cystic Fibrosis (PROSPECT)". identify and validate biomarkers that might reflect partial restoration of CFTR function and can be used to monitor disease progression, and ii) evaluate the mechanistic effects of CFTR modulators and other relevant therapies in individuals with CF

What is the current status of trial NCT02477319?

This trial is currently completed. The enrollment target is 452 participants. The study started on 2015-03. Estimated completion is 2018-07-27.

What conditions does trial NCT02477319 study?

This clinical trial studies the following conditions: Cystic Fibrosis.

What interventions are being tested in trial NCT02477319?

The interventions under investigation include: Observational (OTHER).

Who is sponsoring clinical trial NCT02477319?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02477319 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cystic Fibrosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02477319's enrollment target sits among peer trials

452 14th of 169 higher than 156 of 169 other Cystic Fibrosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cystic Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05676255 · 452 participants · Phase 2

    The Breast Cancer Survivors and Partners Online Research Together (SUPORT) Project

  • NCT05703178 · 452 participants · Phase 3

    Web-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia

  • NCT03460977 · 453 participants · Phase 1

    A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

  • NCT04708171 · 453 participants

    The PROGRAM-study: Awake Mapping Versus Asleep Mapping Versus No Mapping for Glioblastoma Resections

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02477319, the US trial registry maintained by the National Library of Medicine. NCT02477319 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.